IP Library Granted Patent US 7,052,887
Granted Patent B2
US 7,052,887 · App. 10/181,090 · Granted May 30, 2006

Method for immobilization of (an) affinity reagent(s) on a hydrophobic solid phase

Assignee: Bio-Rad Pasteur
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,052,887
App. No.
10/181,090
Granted
May 30, 2006
Kind
B2
Abstract

The invention relates to a method of immobilizing an affinity reagent or affinity reagents on a hydrophobic solid phase which can be used in biological assays for analyte detection. The invention relates more particularly to a method of immobilizing an affinity reagent on a hydrophobic solid phase functionalized by a carboxyl group, said method comprising a step for activation of said solid phase and a step for coupling of the affinity reagent to said solid phase, characterized in that the step for activation of said solid phase uses a combination of a carbodiimide and a phosphate buffer in the presence of a co-activator and in an acid medium, and in that the coupling step is performed in a basic medium. The invention further relates to the reactive complexes obtained by this method and to their use in immunoassay kits, hybridization kits or enzymatic assay kits.

Claims (11)

1. Method of immobilizing an affinity reagent on a hydrophobic solid phase functionalized by a carboxyl group, said method comprising a step for activation of said solid phase and a step for coupling of the affinity reagent to said solid phase, wherein the step for activation of said solid phase uses a combination of a carbodiimide and a phosphate buffer in the presence of a co-activator and in an acid medium with a pH ranging from about 4 to about 6.5, and the coupling step is performed in a basic medium with a pH ranging from about 7.2 to about 10.5.

2. Method according to claim 1 , wherein the carbodiimide used is a compound selected from the group comprising CMC (N-cyclohexyl-N′-(2-morpholinoethyl)carbodiimide methyl-p-toluenesulfonate) and EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide).

3. Method according to claim 1 wherein the co-activator used is a compound selected from the group comprising s-NHS (sulfo-N-hydroxysuccinimide), HOBt (1-hydroxybenzotriazole) and N-hydroxysuccinimide.

4. Method according to claim 1 wherein the carbodiimide used is CMC (N-cyclohexyl-N′-(2-morpholinoethyl)carbodiimide methyl-p-toluenesulfonate) and the co-activator used is s-NHS (sulfo-N-hydroxysuccinimide).

5. Method according to claim 1 , wherein the carbodiimide is used in an amount of 20 to 50 molar equivalents per COOH group.

6. Method according to claim 1 , wherein the co-activator is used in an amount of 3 to 10 molar equivalents per COOH group.

7. Method according to claim 1 , wherein the step for activation of the solid phase uses a combination of 20 to 50 molar equivalents per COOH group of CMC, in 30–200 mM phosphate buffer, in the presence of 3 to 10 molar equivalents per COOH group of sulfo-N-hydroxysuccinimide co-activator, in an acid medium with a pH ranging from about 4 to about 6.5, and in that the coupling is performed in a basic medium with a pH ranging from about 7.2 to out 10.5.

8. Method according to claim 1 , wherein the step for activation of the solid phase uses a combination of 30 molar equivalents per COOH group of CMC, in 50 mM KH 2 P 4 phosphate buffer, in the presence of 5 molar equivalents per COOH group of sulfo-N-hydroxysuccinimide co-activator, at pH 6, and the coupling is performed in a medium containing one volume of a buffer of pH 8.5 and one volume of said phosphate buffer.

9. Method according to claim 1 , wherein the affinity reagent contains an amine group.

10. Method according to claim 9 , wherein the affinity reagent is selected from the group comprising proteins, peptides, immunoglobulins, antigens, haptens, antibodies, enzymes, enzyme substrates, oligonucleotides and polynucleotides.

11. Reactive solid complex obtained by a method according to claim 1 , said reactive solid complex selected from the group consisting of solid phase/antigen complexes, solid phase/protein complexes, solid phase/peptide complexes, solid phase/hapten complexes, solid phase/antibody complexes, solid phase/immunoglobulin complexes, solid phase/oligonucleotide complexes, solid phase/polynucleotide complexes, solid phase/enzyme complexes and solid phase/enzyme substrate complexes.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2019
From: BIO-RAD INNOVATIONS
To: BIO-RAD EUROPE GMBH
Reel/Frame 049122/0754 →
CHANGE OF NAME Recorded Sep 29, 2011
From: BIO-RAD PASTEUR
To: BIO-RAD INNOVATIONS
Reel/Frame 026992/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2002
From: BABIN, FABIENNE; HAMON, LAURENCE; RIEUNIER, FRANCOIS
To: BIO-RAD PASTEUR
Reel/Frame 013241/0150 →
Priority Claims (1)
FR 00 00376 · Jan 13, 2000 · national
Continuity (1)
Related Publication 20040052797A1 · Mar 18, 2004